Article

Nanoparticles: wave of the future in diagnosis and therapeutics

The use of green gold nanoparticles may have a place in the therapy of cancer and ophthalmic diseases because of the affinity of the gold nanoparticles for the leaky vasculature in those diseases, according to Kattesh Katti, PhD, from Nanotechnology, Physics, and Radiology, University of Missouri, Columbia.

The use of green gold nanoparticles may have a place in the therapy of cancer and ophthalmic diseases because ofthe affinity of the gold nanoparticles for the leaky vasculature in those diseases, according to Kattesh Katti,PhD, from Nanotechnology, Physics, and Radiology, University of Missouri, Columbia.

"The field of nanomedicine is an emerging medical modality that uses nanoparticles for diagnostic andtherapeutic applications," Dr. Katti said. "The nanoparticles are focused and given a sense of direction sothat, when injected into the tumors, they can provide morphologic information and possible directions for newtherapeutic modalities."

The level of amplification of the therapeutic payload that the use of gold nanoparticles (with about 200,000atoms) provides is not possible with conventional therapy, he said, using bevacizumab (Avastin, Genentech) as anexample. "Super-Avastin" would have hundreds of units of bevacizumab in one particle, he added. In age-relatedmacular degeneration (AMD), the potent dose of a drug such as bevacizumab might allow intraperitoneal injectionsrather than invasive intraocular injections. This therapy has been done in rats with AMD and there was agreat degree of blood vessel shrinkage-80% to 95%, according to Dr. Katti, and corroboratedhistologically.

Since nanoparticles are substantially smaller than a cell, they can be used to focus on small precancerouslesions by targeting unusual cells with nanoparticles with diagnostic capabilities, he said.

"Nanoparticles . . . have an affinity for leaky vasculature in AMD and cancer, and there is a high affinity ofbiocompatible gold nanoparticles toward the vasculature [that] can be used for site-specific delivery andlocalization," Dr. Katti said. "In addition, gold nanoparticles carry substantially increased therapeuticpayloads compared with conventional therapy and they provide opportunities for designing new pharmaceuticals fortreating cancer, AMD, and related diseases."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.